Loading... Please wait... Loading... Please wait...
ESTIMATED
05/09/2024
05/09/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | -$0.03 | -$0.03 | -$0.03 |
| Q2 2024 | 2 | -$0.04 | -$0.03 | -$0.03 |
| Q3 2024 | 0 | -$0.03 | -$0.03 | -$0.03 |
| Q4 2024 | 0 | -$0.03 | -$0.03 | -$0.03 |
Matinas BioPharma Holdings, Inc. last posted its earnings results on Thursday, May 9th, 2024. The company reported $-0.03 earnings per share for the quarter, missing analysts' consensus estimates of $-0.03 by $0. The company had revenue of 0 for the quarter and had revenue of 1.10 M for the year. Matinas BioPharma Holdings, Inc. has generated $0 earnings per share over the last year ($-0.11 diluted earnings per share) and currently has a price-to-earnings ratio of -1.56. Matinas BioPharma Holdings, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/09/2024 | Q1 2024 | -$0.03 | -$0.03 | 0 | $0 | $0 | 03/27/2024 | Q4 2023 | -$0.02 | -$0.02 | -0 | $300,000 | $-1,096,000 | 11/08/2023 | Q3 2023 | -$0.03 | -$0.03 | 0 | $0 | 08/09/2023 | Q2 2023 | -$0.03 | -$0.03 | 0 | $0 | 05/10/2023 | Q1 2023 | -$0.03 | -$0.03 | 0 | $300,000 | $1.10 M | 03/15/2023 | Q4 2022 | -$0.02 | -$0.00 | 0.02 | $1.03 M | $1.06 M | 11/02/2022 | Q3 2022 | -$0.03 | -$0.03 | 0 | $1.06 M | 08/11/2022 | Q2 2022 | -$0.03 | -$0.03 | 0 | $1.06 M | 05/12/2022 | Q1 2022 | -$0.03 | -$0.01 | 0.01 | $0 | 03/08/2022 | Q4 2021 | -$0.03 | -$0.03 | -0 | $450,000 | $-33,300 | 11/08/2021 | Q3 2021 | -$0.02 | -$0.03 | -0.01 | $2.03 M | $0 | 08/10/2021 | Q2 2021 | -$0.02 | -$0.02 | -0.01 | $25,000 | $0 | 05/10/2021 | Q1 2021 | -$0.03 | -$0.02 | 0.01 | $33,333 | 03/29/2021 | Q4 2020 | -$0.03 | -$0.03 | -0 | $1.28 M | $62,500 | 11/06/2020 | Q3 2020 | -$0.03 | -$0.03 | -0 | $24,536 | $95,833 | 08/10/2020 | Q2 2020 | -$0.03 | -$0.03 | 0 | $24,491 | $0 | 05/11/2020 | Q1 2020 | -$0.03 | -$0.03 | 0 | $0 | 03/09/2020 | Q4 2019 | -$0.03 | -$0.03 | -0 | $27,185 | $-89,812 | 11/13/2019 | Q3 2019 | -$0.03 | -$0.03 | -0 | $11,975 | $0 | 08/13/2019 | Q2 2019 | -$0.03 | -$0.02 | 0 | $33,333 | $89,812 |
|---|
A. Matinas BioPharma Holdings, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 7th, 2024 based off last year's report dates.
A. The conference call for Matinas BioPharma Holdings, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Matinas BioPharma Holdings, Inc.'s latest earnings report can be read online.
A. Matinas BioPharma Holdings, Inc. (AMEX:MTNB) has a recorded annual revenue of $1.10 M.
A. Matinas BioPharma Holdings, Inc. (AMEX:MTNB) has a recorded net income of $1.10 M. Matinas BioPharma Holdings, Inc. has generated $-0.11 earnings per share over the last four quarters.
A. Matinas BioPharma Holdings, Inc. (AMEX:MTNB) has a price-to-earnings ratio of -1.56 and price/earnings-to-growth ratio is -0.2.
